Neuright
Neuright, Inc. is a biotech startup and academic spin-out from the University of Maine, dedicated to developing innovative diagnostic and therapeutic solutions for peripheral neuropathy. Their mission is to provide early detection and better clinical outcomes for patients suffering from this debilitating condition through their theragnostic platform, which combines diagnosis and treatment capabilities. They aim to make neuropathy diagnosis affordable, reliable, and accessible, with the vision of a world free from peripheral neuropathy in all its forms.
Industries
Nr. of Employees
small (1-50)
Neuright
UpStart Center, 20 Godfrey Dr., Suite 211, Orono, ME 04473
Products
Microneedle-based point-of-care nerve activity monitor (diagnostic prototype)
A prototype microneedle-based diagnostic device designed to functionally and quantitatively assess small-fiber peripheral nerve activity in skin and subdermal tissues, intended for point-of-care use and future at-home portability.
Microneedle-based point-of-care nerve activity monitor (diagnostic prototype)
A prototype microneedle-based diagnostic device designed to functionally and quantitatively assess small-fiber peripheral nerve activity in skin and subdermal tissues, intended for point-of-care use and future at-home portability.
Services
Design and run preclinical studies in animal models to optimize device performance and validate therapeutic/diagnostic function.
Partnerships to run first-in-human clinical studies, including device provision, study coordination with clinical teams, and NIH-funded trial execution.
Manufacture of human prototype devices for clinical testing with oversight of device design specifications and production processes to support regulatory compliance.
Development of signal processing and analysis tools to convert measured nerve activity into quantitative diagnostic readouts.
Assistance with early-stage regulatory strategy, FDA pathway initiation, and intellectual property filing including provisional patent submissions.
Design and run preclinical studies in animal models to optimize device performance and validate therapeutic/diagnostic function.
Partnerships to run first-in-human clinical studies, including device provision, study coordination with clinical teams, and NIH-funded trial execution.
Manufacture of human prototype devices for clinical testing with oversight of device design specifications and production processes to support regulatory compliance.
Development of signal processing and analysis tools to convert measured nerve activity into quantitative diagnostic readouts.
Assistance with early-stage regulatory strategy, FDA pathway initiation, and intellectual property filing including provisional patent submissions.
Expertise Areas
- Peripheral neuropathy diagnostics
- Point-of-care medical device development
- Theragnostic platform development (diagnostic + therapy)
- Preclinical model development and optimization
Key Technologies
- Microneedle-based biosensing
- Nerve electrical activity monitoring
- Point-of-care diagnostic systems
- Integrated drug-delivery with diagnostic platforms
News & Updates
Neuright CEO Magdalena Blaszkiewicz pitched their theragnostic platform at the Top Gun Showcase and won a $25,000 award.
Neuright received $225,000 from NSF STTR to develop its technology for delivery to market, focusing on early diagnosis and nerve regeneration treatments.
NSF Small Business Technology Transfer (STTR) Phase 1 Award
Neuright was awarded $225,000 to develop its prototype MVP device for nerve diagnosis and therapy.
Phase 2 TVSF grant from Ohio Third Frontier
Received $150,000 to begin regulatory processes with the FDA and manufacture devices for clinical trials.
Maine Top Gun program funding
Received $25,000 to put the MVP into clinical trials.
Patent Filing
A provisional patent was submitted in May 2020 for their device.
Neuright CEO Magdalena Blaszkiewicz pitched their theragnostic platform at the Top Gun Showcase and won a $25,000 award.
Neuright received $225,000 from NSF STTR to develop its technology for delivery to market, focusing on early diagnosis and nerve regeneration treatments.
NSF Small Business Technology Transfer (STTR) Phase 1 Award
Neuright was awarded $225,000 to develop its prototype MVP device for nerve diagnosis and therapy.
Phase 2 TVSF grant from Ohio Third Frontier
Received $150,000 to begin regulatory processes with the FDA and manufacture devices for clinical trials.
Maine Top Gun program funding
Received $25,000 to put the MVP into clinical trials.
Patent Filing
A provisional patent was submitted in May 2020 for their device.